Natera Announces Senior Leadership Appointments
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced three appointments within its senior leadership team, effective immediately.
- Solomon Moshkevich has been promoted to president of clinical diagnostics and will lead Natera’s team of general managers across oncology, women’s health, and organ health. In addition, Moshkevich will have responsibility for customer service, clinical trial operations, program management, and regulatory and quality affairs.
- Alexey Aleshin, M.D., will succeed Moshkevich, assuming the role of GM of oncology and early cancer detection. Dr. Aleshin will also continue serving as chief medical officer of the company.
- John Fesko has been promoted to president & chief business officer, with oversight of reimbursement strategy and market access, patient operations and experience, marketing and communications, government affairs, business and market development, pharmaceutical services, and international commercial operations and strategy.
“Each of these individuals has demonstrated excellent performance and leadership in their respective areas,” said Steve Chapman, chief executive officer. “As we embark on the next phase of growth at Natera, these appointments of long-tenured executives with significant experience across critical functions will allow us to ensure consistent execution while delivering outstanding service to our patients and customers.”
Solomon Moshkevich, president of clinical diagnostics, joined Natera in 2011. He has played a leading role in the development, clinical validation and commercial success of all Natera’s cell-free DNA products including Panorama, Prospera, and Signatera. He most recently served as general manager of oncology, a position he assumed in 2019, overseeing a period of tremendous growth for the company’s molecular residual disease test, Signatera, and leading the company’s efforts to achieve Medicare coverage for Signatera across multiple cancer types. Moshkevich began his career as a consultant with Bain & Company in New York before joining the private equity investment team at Parthenon Capital in Boston. He graduated from Columbia University summa cum laude with a B.A. in economics and mathematics, and he holds an M.B.A. from Stanford University.
John Fesko, president & chief business officer, joined Natera in 2014. He has held several different leadership roles of increasing responsibility during his tenure. He was named chief business officer in 2019, a role which has grown to include oversight of multiple functions and teams responsible for reimbursement strategy and market access, business and market development, marketing and communications, government affairs, pharmaceutical services, and international commercial operations and strategy. Prior to Natera, Fesko worked at Roche, Novartis Pharma AG, MPM Capital and InVivoScribe. He holds an M.B.A. from M.I.T. and a B.S. in biochemistry and economics from the University of Notre Dame.
Alexey Aleshin, M.D., M.B.A., general manager of oncology and early cancer detection & chief medical officer, joined Natera in 2017. He has served in multiple leadership capacities during his tenure at the company, including vice president of oncology medical affairs, general manager of early cancer detection, and chief medical officer. Prior to Natera, Dr. Aleshin was actively involved as an advisor and consultant at various companies focused on advancing clinical adoption of next generation sequencing technologies. He received his M.D. and M.B.A. from UCLA and later completed his internal medicine residency at Stanford University Medical Center and his hematology/oncology fellowship at Stanford Hospital.
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.